Optimising medication management during the COVID‐19 pandemic

Taskforce of the Therapeutic Goods Administration, facilitated engagement with the key supply chain stakeholders, including Medicines Australia, the National Pharmaceutical Services Association (NPSA) and the Generic and Biosimilar Medicines Association (GBMA) amongst others. Data on medication availability was made available by the pharmaceutical companies. Data on usage in private hospitals was made available from private hospital providers. All our States and Territories were instrumental in providing medication usage data on all ventilated COVID-19 patients. This facilitated the development of a national demand model for these critical medicationspivotal to informing efforts to facilitate access to these medicines.